GLP-1 Metabolic Medicine Foundation Certification

This GLP-1 foundation certification exam is designed for medical doctors, postgraduate medical residents, MD/MS and DNB trainees, NEET-PG and INI-CET (Institute of National Importance Combined Entrance Test) aspirants, AIIMS-PG candidates, FMGE (Foreign Medical Graduate Examination) aspirants, family physicians, internists, endocrinologists, dermatologists, obstetricians, and any clinician who prescribes or plans to prescribe semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), or liraglutide (Victoza, Saxenda). It is also widely used by medical students, interns, and residents as a structured GLP-1 source for postgraduate exam preparation in metabolic medicine, endocrinology, and internal medicine.

Yes. The 127-question bank covers the high-yield GLP-1 receptor agonist topics that appear regularly in NEET-PG (National Eligibility cum Entrance Test for Postgraduate), INI-CET (Institute of National Importance Combined Entrance Test), AIIMS-PG (All India Institute of Medical Sciences Postgraduate Entrance), and FMGE (Foreign Medical Graduate Examination) papers across pharmacology, endocrinology, and general medicine. Each explanation cites the original trial (ACCORD, DiRECT, ReTUNE, EMPA-REG, STEP, SURMOUNT, SELECT, FLOW, LEADER, SUSTAIN-6, SCALE, SURMOUNT-OSA, ESSENCE) with year, journal, and primary endpoint result, which doubles as a focused revision tool for postgraduate medical entrance exams.

Each exam attempt presents 20 single best answer questions, randomly drawn from a bank of 127 evidence-based questions across the paradigm shift in metabolic medicine, SGLT2 inhibitors, GLP-1 mechanism of action, pharmacokinetics and dosing, side effect and safety management, special populations, and the history and evolution of incretin therapy. Question order and option order are shuffled at the start of every attempt. The randomization means every attempt is a fresh exam.

The pass mark is 14 of 20 correct answers, or 70 percent. The threshold reflects a working clinical competence in GLP-1 receptor agonist prescribing, not academic mastery. Candidates who score below 14 of 20 receive the full answer key with evidence-cited explanations for every question they were presented and can retake the exam with a freshly randomized question set as many times as needed.

Yes. There is no limit on retakes. Each attempt draws a fresh random set of 20 questions from the 127-question bank with shuffled option order, so no two attempts are identical. The intent is education first and assessment second. The exam is built as a learning instrument: the full evidence-cited explanation appears on the results screen for every question, whether you answered it correctly or not.

This is an open physician education initiative published by DermaVue Clinics and authored by Dr. Rejeesh M. Menon, MD. It is not a recognized medical license, specialty board certification, government accredited credential, or CME credit. The certificate reflects completion of a structured self-assessed knowledge evaluation on GLP-1 receptor agonist therapy. It is suitable for personal learning portfolios and for demonstrating engagement with the field, but it does not replace formal medical licensing or board certification.

The 127-question bank was developed by Dr. Rejeesh M. Menon, MD (Internal Medicine, faculty at Washington State University, Medical Director DermaVue Clinics), drawing on primary literature including the ACCORD, DiRECT, ReTUNE, EMPA-REG OUTCOME, DAPA-HF, EMPEROR-Reduced, STEP, SURMOUNT, SUSTAIN, SELECT, FLOW, LEADER, and Counterpoint trial publications, Roy Taylor Twin Cycle hypothesis papers, Daniel Drucker Cell Metabolism reviews, Jens Holst Physiological Reviews papers, ADA Standards of Care 2024, KDIGO Diabetes in CKD 2022, ASA 2023 perioperative guidance, ICMR-INDIAB-17, the Misra consensus 2009, and ICMR PCOS Task Force 2023. Every question carries a peer-reviewed citation.

The bank covers seven domains. The paradigm shift in metabolic medicine (ACCORD, Twin Cycle, Counterpoint, DiRECT, ReTUNE, Yajnik thin-fat phenotype, Indian BMI thresholds). SGLT2 inhibitors as proof that glucose is not the disease (EMPA-REG, DAPA-HF, EMPEROR-Reduced). GLP-1 mechanism of action (four pillars, glucose-dependent insulinotropy, POMC and AgRP arcuate signaling, vagal afferents and gastric emptying, mesolimbic reward and food noise, dual GIP/GLP-1 tirzepatide, SELECT, FLOW). Pharmacokinetics and drug design (half-lives, Aib at position 2, C18 fatty acid albumin binding, semaglutide and tirzepatide titration, Rybelsus SNAC absorption, missed dose protocols, Indian generic market after the March 2026 patent expiry). Side effects and safety (nausea via area postrema, MTC and MEN-2, pancreatitis red flag, lean mass loss, gallstones, pregnancy washout, perioperative hold, AKI, hypoglycemia with insulin or sulfonylurea). Special populations (adolescents, type 1 diabetes, CKD, hepatic impairment, PCOS, post-bariatric). History and evolution (Habener 1980s proglucagon work, Gila monster exendin-4, Saxenda 2014).

Yes. Candidates who score 14 of 20 or higher (70 percent or above) receive a PDF certificate of completion, downloadable from the results screen. The certificate is generated client side using jsPDF, formatted on A4 in horizontal orientation with a gold accent border, and is signed by Dr. Rejeesh M. Menon MD (Internal Medicine, faculty Washington State University, Medical Director DermaVue Clinics) and Dr. Sarath Chandran MD DVL (Managing Director, DermaVue Clinics) with their handwritten signatures embedded. Each certificate carries a unique identifier in the format SH-CERT-XXXXXX for record keeping.